Title: | Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk |
Journal: | Mayo Clinic Proceedings |
Published: | 9 Apr 2025 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40196966/ |
DOI: | https://doi.org/10.1016/j.mayocp.2024.11.024 |
Title: | Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk |
Journal: | Mayo Clinic Proceedings |
Published: | 9 Apr 2025 |
Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40196966/ |
DOI: | https://doi.org/10.1016/j.mayocp.2024.11.024 |
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
OBJECTIVE: To assess the long-term association between benign prostatic hyperplasia (BPH) and chronic kidney disease (CKD) while considering the potential role of BPH medications in any observed associations.</p>
METHODS: This study used a prospective cohort design. A total of 198,399 male patients without CKD at baseline were recruited from the UK Biobank from 2006 to 2010. Cox proportional hazards models were used to analyze the relationships between BPH, its medication, and the incidence of CKD and end-stage kidney disease (ESKD).</p>
RESULTS: After a median follow-up of 13.58 years, 3710 patients with BPH were diagnosed with CKD (hazard ratio [HR], 1.26; 95% CI, 1.10 to 1.45), and 322 patients with BPH were diagnosed with ESKD (HR, 1.49; 95% CI, 0.72 to 3.08), compared with non-BPH patients. Furthermore, BPH medication significantly increased the risk of CKD (HR, 1.48; 95% CI, 1.18 to 1.85) in individuals with BPH compared with those without medication.</p>
CONCLUSION: This study found that people with BPH and those taking BPH medications have a higher long-term risk of CKD. Benign prostatic hyperplasia may contribute to the progression of CKD to ESKD. These findings highlight the importance of monitoring kidney function in patients with BPH.</p>
Enabling scientific discoveries that improve human health